Navigation Links
Cepheid to Webcast Upcoming Financial Presentations
Date:2/1/2012

SUNNYVALE, Calif., Feb. 1, 2012 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced that its executives will be speaking at the following investor conferences, and invited investors to participate via webcast.

Leerink Swann Global Healthcare Conference, New York, NY
Wednesday, February 15, 2012 at 11.30 a.m. Eastern Time

Raymond James Annual Conference, Orlando, FL
Tuesday, March 6, 2012 at 1.05 p.m. Eastern Time

Additionally, Cepheid announced that it will participate in The NASDAQ Opening Bell ceremony at The NASDAQ Stock Market on Tuesday, February 7, 2012. The ceremony commemorates the continued growth and innovation of Cepheid's GeneXpert® system which saw record placements in 2011, and will take place at 9:30 a.m. Eastern Time at The NASDAQ MarketSite Studio in Times Square, New York City.

Accessing Live Webcasts To access the live webcasts for the two investor conferences, please visit Cepheid's website at www.cepheid.com/investors at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software.  A replay of the webcasts will be available shortly following the presentation and will remain available for at least 90 days.

About CepheidBased in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy to use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to access the full power of molecular diagnostics. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit www.cepheid.com

CONTACTS:

 

  For Media Inquiries: For Investor Inquiries:  

Jared Tipton

Cepheid Corporate Communications

Tel: (408) 400-8377

communications@cepheid.com

Jacquie Ross

Cepheid Investor Relations

Tel: (408) 400-8329

investor.relations@cepheid.com

 

 


'/>"/>

SOURCE Cepheid
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cepheid Reports Fourth Quarter and Full Year 2011 Results
2. Cepheid Welcomes Senior Vice President of Human Resources
3. Cepheid Receives FDA Clearance for Xpert Flu, Delivering Simultaneous Detection and Differentiation of Flu A, Flu B, and 2009 H1N1 Strain
4. Cepheid Schedules 2010 Third Quarter Financial Results Announcement and Webcast
5. Cepheid to Webcast Upcoming Financial Presentations
6. Cepheid Expands Leadership Team With Appointment of Executive Vice President of Worldwide Commercial Operations
7. Cepheid Schedules 2009 Third Quarter Financial Results Announcement and Webcast
8. Cepheid Schedules 2009 Second Quarter Financial Results Announcement and Webcast
9. Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
10. Cepheid Reports 2009 First Quarter Results
11. Cepheid Schedules Fiscal 2009 First Quarter Financial Results Announcement and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)...  VMS BioMarketing, a leading provider of patient support solutions, ... Educator (CNE) network, which will launch this week. The VMS ... care professionals to enhance the patient care experience by delivering ... health care professionals to help women who have been diagnosed ... ...
(Date:10/11/2017)... ... 2017 , ... Disappearing forests and increased emissions are the main causes of ... year. Especially those living in larger cities are affected by air pollution related diseases. ... most pollution-affected countries globally - decided to take action. , “I knew I had ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and ... of osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular ...
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... anticipated to expand at a CAGR of 25.76% during ... diseases is the primary factor for the growth of ... report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global ... product, technology, application, and geography. The stem cell market ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/30/2017)... HONG KONG , March 30, 2017 ... developed a system for three-dimensional (3D) fingerprint identification by adopting ground ... technology into a new realm of speed and accuracy for use ... applications at an affordable cost. ... ...
Breaking Biology News(10 mins):